Pathogenic Factors Identification of Brain Imaging and Gene in Late Mild Cognitive Impairment.

Interdisciplinary Sciences, Computational Life Sciences
Xia-An BiZhaoxu Xing

Abstract

Mild cognitive impairment (MCI) is a dangerous signal of severe cognitive decline. It can be separated into two steps: early MCI (EMCI) and late MCI (LMCI). As the post-state of MCI and pre-state of Alzheimer's disease (AD), LMCI receives insufficient attention in the field of brain science, causing the internal mechanism of LMCI has not been well understood. To better explore the focus and pathological mechanism of LMCI, a method called genetic evolved random forest (GERF) is applied. Resting functional magnetic resonance imaging (rfMRI) and gene data are obtained from 62 subjects (36 LMCI and 26 normal controls), and Pearson correlation analysis is adopted to perform the multimodal fusion of two types of data to construct fusion features. We identified pathogenic brain regions and genes that are highly related to LMCI using GERF and achieves a good effect. Compared with the normal control (NC) group, the abnormal brain regions of LMCI are PUT.L, PreCG.L, IFGtriang.R, REC.R, DCG.R, PoCG.L, and HES.L, and the pathogenic genes are FHIT, RF00019, FRMD4A, PTPRD, and RBFOX1. More importantly, most of these risk genes and abnormal brain regions have been confirmed to be related to AD and MCI in previous studies. In this study, we ma...Continue Reading

References

Feb 5, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Frank JessenUNKNOWN German Study on Aging, Cognition and Dementia in Primary Care Patients
Mar 20, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Apr 23, 2013·Interdisciplinary Sciences, Computational Life Sciences·A M AdeshinaS Z Z Abidin
Jul 1, 2012·Journal of the American Statistical Association·Runze LiLiping Zhu
Dec 3, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Alicia D RuedaUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 25, 2015·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Ali KhazaeeAbbas Babajani-Feremi
Jan 25, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Vamsidhar VelchetiSiraj M Ali
Mar 30, 2017·The Neuroradiology Journal·K A SmithaChandrasekharan Kesavadas
Jun 18, 2017·Journal of Health Care Chaplaincy·Katherine R B JankowskiLaura T Flannelly
Oct 3, 2017·Bioinformatics·Lei DuUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Oct 7, 2017·Journal of Alzheimer's Disease : JAD·Joel HuovinenVille Leinonen
Nov 16, 2018·Molecular Therapy. Nucleic Acids·Xing ChenZhu-Hong You
Jan 1, 2019·Annals of Translational Medicine·Ling-Li KongUNKNOWN Alzheimer’s Disease Neuroimaging Initiative*
Feb 18, 2019·Methods : a Companion to Methods in Enzymology·Ran SuQuan Zou
Feb 25, 2019·NeuroImage. Clinical·Xin ZhangUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Sep 8, 2019·NeuroImage. Clinical·Chong-Yaw WeeUNKNOWN Alzheimers Disease Neuroimage Initiative
Sep 3, 2020·Interdisciplinary Sciences, Computational Life Sciences·Xiaoxue XuZhiyi He
Feb 26, 2021·BioMed Research International·Juan ZhouLiyue Liu
Mar 23, 2021·IEEE Journal of Biomedical and Health Informatics·Xia-An BiZhaoxu Xing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.